Skip to main content

Need to avoid ‘vaccine nationalism’

vaccine nationalism

WITH at least 14 vaccines now in play, it is not surprising that powerful nations such as the USA, EU, UK, Russia, China and others have rushed to stockpile them for the benefit of their citizens. This is more so as these countries, despite their sophisticated healthcare systems, have been severely affected by the coronavirus scourge in terms of number of people infected and fatalities.

The scramble for available vaccines should be approached with caution to avoid what the World Health Organisation has correctly termed “vaccine nationalism”. According to the World Economic Forum, WEF, “vaccine nationalism” occurs when countries push to get first access.

“The richest nations have secured billions of COVID-19 doses, while developing countries struggle for supplies”. Many of the advanced countries end up stockpiling far more than they may need while the poor nations are left behind and running the risk of buying at exorbitant prices.

The WHO has been criticised for many failures since the pandemic emerged in China in December 2019, but it has been very proactive in efforts to ensure that vaccines and other treatment options are equitably available to countries irrespective of the size of their pockets.

In April 2020 it initiated the Access to COVID-19 Tools, ACT, Accelerator which designed the COVID-19 Vaccine, COVAX, in partnership with GAVI, the Vaccine Alliance, the Centre for Epidemics Preparedness Innovations, CEPI, and others to ensure that all countries will have access to vaccines. This has attracted 156 economies so far.

ALSO READ: Nigeria spends over N500bn on tobacco-related illnesses annually – Researcher

We commend the WHO and partners for this initiative whose importance can never be understated. This is the first worldwide pandemic in the globalised era.

Visionaries like Bill Gates warn that perhaps more vicious pandemics might be here pretty soon. We must use the experience of the COVID-19 pandemic to adjust the world’s mindset towards a greater tendency to share resources rather than monopolise them.

We must put more emphasis on our common humanity rather than the supremacy of the highest bidder.

It is in the interest of all that vaccines go round where they are needed irrespective of financial power.

If the pandemic is allowed to fester in some corners of the world, the risk of mutations to more dangerous variants will increase and we may live with this pandemic for much longer than necessary.

The WEF has even determined that richer economies will have to spend $119 billion per annum if the $25 billion required to make vaccines universally available is not realised.

We are all in this COVID-19 war together. To effectively eradicate it in record time, we must continue to close ranks.

We must continue to share efforts and resources, knowing that whatever is allowed to go round will always come round.

Vanguard News Nigeria

The post Need to avoid ‘vaccine nationalism’ appeared first on Vanguard News.


by Emmanuel Okogba via Vanguard News https://ift.tt/3bO5c4X Best Known Member of the Cabinet Wikipedia

Comments

Popular posts from this blog

Effective Data Governance: IIM-Africa inks partnership deal with Data Management University

President/Chairman of the governing council of IIM-Africa, Dr. Oyedokun Oyewole has said that effective data governance strategy has become more essential for the survival and sustenance of government and businesses, especially with the sudden outbreak of COVID-19 Pandemic. Oyewole said there is the need to ensure that the right policies, processes, technology, and people are in place to effectively manage data while complying with legal and regulatory requirements. He said that as part of the IIM Africa’s commitments towards ensuring global best practices, it has entered into a long-term partnership with DataManagementU.com to bring the finest data management training to industries across Africa. READ ALSO:  COVID-19: Foreign affairs minister says first set of Nigerians abroad to be evacuated soon According to the IIM President, the alliance is expected to provide members of the Institute and other professionals across Africa, high standards, internationally-recognized learn...

Naomi Osaka’s statement about withdrawing from French Open

Japan’s Naomi Osaka returns the ball to Romania’s Patricia Maria Tig during their first round match of the French open tennis tournament at the Roland Garros stadium Sunday, May 30, 2021 in Paris. (AP Photo/Christophe Ena) Naomi Osaka tweeted the following statement announcing her withdrawal from the French Open on Monday: “Hey everyone, this isn’t a situation I ever imagined or intended when I posted a few days ago. I think now the best thing for the tournament, the other players and my well-being is that I withdraw so that everyone can get back to focusing on the tennis going on in Paris. ”I never wanted to be a distraction and I accept that my timing was not idea and my message could have been clearer. ”More importantly I would never trivialize mental health or use the term lightly. The truth is that I have suffered long bouts of depression since the US Open in 2018 and I have had a really hard time coping with that. Anyone that knows me knows I’m introverted, and anyone tha...

Remdesivir: The COVID-19 drug helping patients recover faster

A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. PHOTO: AP Remdesivir has been shown to speed up recovery times for patients with COVID-19 in a major US-led trial, becoming the first drug with proven benefit against the disease. Here is what you need to know. – What is remdesivir? – Remdesivir is an experimental, broad spectrum antiviral made by US pharmaceutical Gilead Sciences that was first developed to treat Ebola, a viral hemorrhagic fever. It showed early promise in a primate study in 2016 and was later rolled out for a major trial in the Democratic Republic of Congo, where it was compared against three other medicines. That study concluded in 2019 when it was discontinued because it did not boost survival rates as greatly as two monoclonal antibody drugs, which are lab-engineered immune system proteins. In February, the US National Institute of Allergy and Infectious Diseases (NIAID) announced ...